A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic

Josh Sullivan

Liver disease is one of the hardest therapeutic areas to hit, and some researchers have pointed to a dearth of meaningful preclinical models during drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic

Josh Sullivan

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

Boehringer’s updated results in HER2-mutated lung cancer impress

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

A UK biotech looks to up­set the pre­clin­i­cal mod­el for liv­er drug de­vel­op­ment, and now it's gear­ing up for the clin­ic

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic